Adrenergic signaling at the interface of allergic asthma and viral infections

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Upper respiratory viral infections are a major etiologic instigator of allergic asthma, and they drive severe exacerbations of allergic inflammation in the lower airways of asthma sufferers. Rhinovirus (RV), in particular, is the main viral instigator of these pathologies. Asthma exacerbations due to RV infections are the most frequent reasons for hospitalization and account for the majority of morbidity and mortality in asthma patients. In both critical care and disease control, long- and short-acting β2-agonists are the first line of therapeutic intervention, which are used to restore airway function by promoting smooth muscle cell relaxation in bronchioles. While prophylactic use of β2-agonists reduces the frequency and pathology of exacerbations, their role in modulating the inflammatory response is only now being appreciated. Adrenergic signaling is a component of the sympathetic nervous system, and the natural ligands, epinephrine and norepinephrine (NE), regulate a multitude of autonomic functions including regulation of both the innate and adaptive immune response. NE is the primary neurotransmitter released by post-ganglionic sympathetic neurons that innervate most all peripheral tissues including lung and secondary lymphoid organs. Thus, the adrenergic signaling pathways are in direct contact with both the central and peripheral immune compartments. We present a perspective on how the adrenergic signaling pathway controls immune function and how β2-agonists may influence inflammation in the context of virus-induced asthma exacerbations.

Original languageEnglish (US)
Article number736
JournalFrontiers in Immunology
Volume9
Issue numberAPR
DOIs
StatePublished - Apr 11 2018

Fingerprint

Virus Diseases
Adrenergic Agents
Asthma
Rhinovirus
Norepinephrine
Pathology
Inflammation
Bronchioles
Muscle Relaxation
Sympathetic Nervous System
Adaptive Immunity
Critical Care
Innate Immunity
Respiratory Tract Infections
Epinephrine
Smooth Muscle Myocytes
Neurotransmitter Agents
Hospitalization
Ligands
Viruses

Keywords

  • Adrenergic receptor
  • Asthma
  • Cytokine
  • Inflammation
  • Rhinovirus

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Adrenergic signaling at the interface of allergic asthma and viral infections. / Agaç, Didem; Gill, Michelle A.; Farrar, J. David.

In: Frontiers in Immunology, Vol. 9, No. APR, 736, 11.04.2018.

Research output: Contribution to journalArticle

@article{1d62cc3a0bdf4bffbea29d08eed40ad6,
title = "Adrenergic signaling at the interface of allergic asthma and viral infections",
abstract = "Upper respiratory viral infections are a major etiologic instigator of allergic asthma, and they drive severe exacerbations of allergic inflammation in the lower airways of asthma sufferers. Rhinovirus (RV), in particular, is the main viral instigator of these pathologies. Asthma exacerbations due to RV infections are the most frequent reasons for hospitalization and account for the majority of morbidity and mortality in asthma patients. In both critical care and disease control, long- and short-acting β2-agonists are the first line of therapeutic intervention, which are used to restore airway function by promoting smooth muscle cell relaxation in bronchioles. While prophylactic use of β2-agonists reduces the frequency and pathology of exacerbations, their role in modulating the inflammatory response is only now being appreciated. Adrenergic signaling is a component of the sympathetic nervous system, and the natural ligands, epinephrine and norepinephrine (NE), regulate a multitude of autonomic functions including regulation of both the innate and adaptive immune response. NE is the primary neurotransmitter released by post-ganglionic sympathetic neurons that innervate most all peripheral tissues including lung and secondary lymphoid organs. Thus, the adrenergic signaling pathways are in direct contact with both the central and peripheral immune compartments. We present a perspective on how the adrenergic signaling pathway controls immune function and how β2-agonists may influence inflammation in the context of virus-induced asthma exacerbations.",
keywords = "Adrenergic receptor, Asthma, Cytokine, Inflammation, Rhinovirus",
author = "Didem Aga{\cc} and Gill, {Michelle A.} and Farrar, {J. David}",
year = "2018",
month = "4",
day = "11",
doi = "10.3389/fimmu.2018.00736",
language = "English (US)",
volume = "9",
journal = "Frontiers in Immunology",
issn = "1664-3224",
publisher = "Frontiers Media S. A.",
number = "APR",

}

TY - JOUR

T1 - Adrenergic signaling at the interface of allergic asthma and viral infections

AU - Agaç, Didem

AU - Gill, Michelle A.

AU - Farrar, J. David

PY - 2018/4/11

Y1 - 2018/4/11

N2 - Upper respiratory viral infections are a major etiologic instigator of allergic asthma, and they drive severe exacerbations of allergic inflammation in the lower airways of asthma sufferers. Rhinovirus (RV), in particular, is the main viral instigator of these pathologies. Asthma exacerbations due to RV infections are the most frequent reasons for hospitalization and account for the majority of morbidity and mortality in asthma patients. In both critical care and disease control, long- and short-acting β2-agonists are the first line of therapeutic intervention, which are used to restore airway function by promoting smooth muscle cell relaxation in bronchioles. While prophylactic use of β2-agonists reduces the frequency and pathology of exacerbations, their role in modulating the inflammatory response is only now being appreciated. Adrenergic signaling is a component of the sympathetic nervous system, and the natural ligands, epinephrine and norepinephrine (NE), regulate a multitude of autonomic functions including regulation of both the innate and adaptive immune response. NE is the primary neurotransmitter released by post-ganglionic sympathetic neurons that innervate most all peripheral tissues including lung and secondary lymphoid organs. Thus, the adrenergic signaling pathways are in direct contact with both the central and peripheral immune compartments. We present a perspective on how the adrenergic signaling pathway controls immune function and how β2-agonists may influence inflammation in the context of virus-induced asthma exacerbations.

AB - Upper respiratory viral infections are a major etiologic instigator of allergic asthma, and they drive severe exacerbations of allergic inflammation in the lower airways of asthma sufferers. Rhinovirus (RV), in particular, is the main viral instigator of these pathologies. Asthma exacerbations due to RV infections are the most frequent reasons for hospitalization and account for the majority of morbidity and mortality in asthma patients. In both critical care and disease control, long- and short-acting β2-agonists are the first line of therapeutic intervention, which are used to restore airway function by promoting smooth muscle cell relaxation in bronchioles. While prophylactic use of β2-agonists reduces the frequency and pathology of exacerbations, their role in modulating the inflammatory response is only now being appreciated. Adrenergic signaling is a component of the sympathetic nervous system, and the natural ligands, epinephrine and norepinephrine (NE), regulate a multitude of autonomic functions including regulation of both the innate and adaptive immune response. NE is the primary neurotransmitter released by post-ganglionic sympathetic neurons that innervate most all peripheral tissues including lung and secondary lymphoid organs. Thus, the adrenergic signaling pathways are in direct contact with both the central and peripheral immune compartments. We present a perspective on how the adrenergic signaling pathway controls immune function and how β2-agonists may influence inflammation in the context of virus-induced asthma exacerbations.

KW - Adrenergic receptor

KW - Asthma

KW - Cytokine

KW - Inflammation

KW - Rhinovirus

UR - http://www.scopus.com/inward/record.url?scp=85045243803&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045243803&partnerID=8YFLogxK

U2 - 10.3389/fimmu.2018.00736

DO - 10.3389/fimmu.2018.00736

M3 - Article

C2 - 29696025

AN - SCOPUS:85045243803

VL - 9

JO - Frontiers in Immunology

JF - Frontiers in Immunology

SN - 1664-3224

IS - APR

M1 - 736

ER -